

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	:	
	:	Confirmation No. 3314
Gerald Cagle et al.	:	
	:	Group Art Unit: 1618
Application No. 10/715,055	:	
	:	Examiner: Fay, Zohreh A.
Filed: November 17, 2003	:	
	:	Atty Dkt No.: 007109.00001
For: METHOD OF TREATING	:	
OPHTHALMIC INFECTIONS WITH	:	
MOXIFLOXACIN COMPOSITIONS	:	

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Customer Service Window  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Sir:

Pursuant to the duty of disclosure under 37 CFR §§ 1.56 and 1.97-1.98, the document listed on the attached PTO form PTO/SB/08a is being brought to the attention of the Examiner. The Examiner is requested to initial the space adjacent the document's entry on the form and to return a copy of the initialed form to confirm that the document has been considered and has been officially made of record in this application.

Applicants' Information Disclosure Statement ("IDS") filed May 31, 2008 cited Defendant Teva's post-trial briefs from the litigation *Bayer Healthcare AG, Alcon, Inc. and Alcon Research, Ltd. v. Teva Pharmaceuticals USA, Inc.*, Civil Action No. 06-234 (SLR), involving the parent '830 patent. The Plaintiffs' post-trial brief on validity was cited in an IDS filed July 9, 2008. The present IDS cites Defendant Teva's post-trial reply brief on invalidity.

The Examiner is invited to telephone the undersigned at the number listed below if doing so would be helpful to resolve any outstanding issues.

Respectfully submitted,  
BANNER & WITCOFF, LTD.

Date: August 5, 2008

1100 13<sup>th</sup> Street N.W.  
Suite 1200  
Washington, DC 20005-4051  
(202) 824-3000 (telephone)  
(202) 824-3001 (facsimile)

By: /Paul M. Rivard/  
Paul M. Rivard  
Registration No. 43,446